GRML — what changed in the latest 10-Q
A section-by-section comparison of GRML's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-17 vs the prior 10-Q · 2026-05-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +60 | −22 | ~5 | 2 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | +1 | −2 | ~6 | 2 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings, Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-17
On March 4, 2026, we completed the acquisition of Greenland Mines Corp., resulting in a significant strategic transformation. Through the transaction, we acquired an indirect 80% interest in the Skaergaard Project, a large-scale mineral exploration asset located in southeast Greenland, and expanded …
As a result of the acquisition, we operate through two reportable segments: (i) Biotech and (ii) Mining. Our Biotech segment continues to focus on research and development activities, and our Mining segment focuses on the exploration and development of mineral resources. This expansion represents a …
Our Biotech segment is focused on the development of therapies for chronic and neurodegenerative diseases. Our biotechnology platform includes a gene therapy platform designed to deliver the “Klotho” protein for the treatment of neurodegenerative diseases, with our lead program, KLTO-202, targeting …
On May 20, 2026, we entered into an Agreement and Plan of Merger to acquire Neo North Star Resources, Inc., the holder of the Sarfartoq Rare Earth Element Project in southwest Greenland, from its stockholders, including Neo Performance Materials. Total consideration is $35.0 million, consisting of $…
On June 22, 2026, we completed a share exchange with AnorTech Inc., issuing 12,400,000 shares of our common stock in exchange for common shares representing approximately 9.9% of AnorTech’s outstanding common stock, together with an option to acquire additional AnorTech shares. We recorded the inves…
Text removed vs the prior filing · source: 10-Q · 2026-05-20
During the quarter ended March 31, 2026, the Company underwent a significant strategic transformation as a result of the acquisition of Greenland Mines Corp., which was completed on March 4, 2026. Through this transaction, the Company acquired an interest in the Skaergaard Project, a large-scale min…
In connection with this transaction, on March 11, 2026, the Company changed its legal name from Klotho Neurosciences, Inc. to Greenland Mines Ltd, and its common stock began trading under the ticker symbol “GRML” on the Nasdaq Capital Market effective March 12, 2026.
As a result of the March 2026 acquisition, the Company now operates through two primary business segments: (i) Biotech and (ii) Mining. The Biotech segment continues to focus on research and development activities, while the Mining segment focuses on the exploration and development of mineral resour…
Prior to the March 2026 transaction, the Company operated as a biotechnology-focused entity developing essential medicines for the treatment of chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The Company’s biotechnology platform includes a generic drug portfolio,…
Effective September 17, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc. This name change was approved by the Company’s Board of Directors to better reflect the strategic focus of its proprietary products. Throughout these financial statements, reference…
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-17
These remediation efforts are ongoing, and the material weaknesses described above had not been fully remediated as of June 30, 2026. Notwithstanding the material weaknesses, management believes that our condensed consolidated financial statements for the three and six months ended June 30, 2026 are…
Text removed vs the prior filing · source: 10-Q · 2026-05-20
● Tested key controls to verify operating effectiveness as of March 31, 2026
Accordingly, management believes that our financial statements for the quarter ended March 31, 2026 are fairly stated, in all material respects, in accordance with GAAP.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice